Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Its principal product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. The company also develops CPP-115, a vigabatrin analog to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-22.5%||ROE||-25.68%||ROI|
|Current Ratio||12.99||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||36.06 M||Cash From Investing Activities||-40 K||Cash From Operating Activities||-3.79 M||Gross Profit|
|Net Profit||-5.41 M||Operating Profit||-4.29 M||Total Assets||76.05 M||Total Current Assets||75.97 M|
|Total Current Liabilities||5.85 M||Total Debt||Total Liabilities||9.43 M||Total Revenue|
|High 52 week||6.11||Low 52 week||1.92||Last close||5.03||Last change||-0.98%|
|RSI||75.81||Average true range||0.28||Beta||0.62||Volume||310.27 K|
|Simple moving average 20 days||7.3%||Simple moving average 50 days||22.15%||Simple moving average 200 days||42.18%|
|Performance Week||-0.59%||Performance Month||23.59%||Performance Quart||60.19%||Performance Half||103.64%|
|Performance Year||71.67%||Performance Year-to-date||161.98%||Volatility daily||2.68%||Volatility weekly||6%|
|Volatility monthly||12.3%||Volatility yearly||42.6%||Relative Volume||298.06%||Average Volume||1.66 M|
|New High||New Low|
2019-09-19 10:37:31 | Should You Wait Before Investing In Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX?
2019-09-18 09:31:01 | Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
2019-09-13 10:00:02 | Catalyst Pharmaceutical CPRX is a Great Momentum Stock: Should You Buy?
2019-09-13 08:41:12 | Implied Volatility Surging for Catalyst CPRX Stock Options
2019-09-11 16:19:39 | Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
2019-09-10 15:18:07 | Investors Can Find Big Returns with this First Profit Screen
2019-09-06 21:48:55 | Edited Transcript of CPRX earnings conference call or presentation 8-Aug-19 12:30pm GMT
2019-09-06 09:31:01 | Why Is Catalyst CPRX Up 23% Since Last Earnings Report?
2019-08-29 08:44:12 | Catalyst Pharmaceuticals CPRX Looks Good: Stock Adds 6% in Session
2019-08-27 14:39:06 | Here's How to Find Top-Ranked Stocks Under $10 to Buy
2019-08-19 12:00:04 | Top Ranked Momentum Stocks to Buy for August 19th
2019-08-16 07:54:11 | Will Catalyst Pharmaceuticals Continue to Surge Higher?
2019-08-13 11:42:40 | Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX: The Best Of Both Worlds
2019-08-08 15:06:00 | Why Catalyst Pharmaceuticals Stock Broke Down Today
2019-08-08 09:26:01 | Catalyst's CPRX Q2 Earnings and Revenues Beat Estimates
2019-08-07 18:55:10 | Catalyst Pharmaceutical CPRX Beats Q2 Earnings and Revenue Estimates
2019-08-01 16:09:00 | 2 Small-Cap Stocks That Could Make You Rich
2019-07-31 09:12:00 | 2 Top Stocks to Buy in August
2019-07-08 08:58:33 | Do Directors Own Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX Shares?
2019-07-08 08:40:12 | Do Options Traders Know Something About Catalyst CPRX Stock We Don't?
2019-07-05 12:04:04 | Catalyst Pharma Focuses on Firdapse Launch & Label Expansion
2019-07-02 12:14:04 | Explosive Stocks Under $10
2019-06-26 14:07:59 | Here is What Hedge Funds Think About Catalyst Pharmaceuticals, Inc. CPRX
2019-06-13 17:46:09 | Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi
2019-06-12 09:46:42 | UPDATE 2-Catalyst Pharma sues FDA over approval of cheaper rival drug
2019-06-12 09:30:01 | Catalyst CPRX Up 14.1% Since Last Earnings Report: Can It Continue?
2019-06-12 09:00:53 | Catalyst Pharma files lawsuit against U.S. FDA on Jacobus Pharma drug approval
2019-06-12 08:47:00 | Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration
2019-06-04 08:03:00 | Catalyst Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
2019-05-30 08:03:00 | Catalyst Pharmaceuticals Announces Expansion of Firdapse License to Include Japan
2019-05-28 14:33:05 | Catalyst Pharmaceuticals settles patent dispute with Northwestern University
2019-05-22 15:47:07 | Catalyst Pharma CPRX Rides on Successful Launch of Firdapse
2019-05-22 12:57:50 | Edited Transcript of CPRX earnings conference call or presentation 13-May-19 12:30pm GMT
2019-05-18 07:15:48 | 5 Biotech Stocks to Watch in the Second Half of 2019
2019-05-16 11:00:00 | Are These 2 Beaten-Down Biotech Stocks Worth the Risk?
2019-05-14 14:36:06 | Catalyst CPRX Q1 Loss Narrows, Firdapse Off to a Good Start
2019-05-14 08:44:12 | Implied Volatility Surging for Catalyst Pharmaceuticals CPRX Stock Options
2019-05-13 14:00:00 | Catalyst Pharmaceuticals Posts Strong Q1 Sales for Firdapse
2019-05-13 13:10:00 | Why Catalyst Pharmaceuticals Briefly Spiked Today
2019-05-13 12:23:14 | Catalyst Pharmaceuticals Inc CPRX Q1 2019 Earnings Call Transcript
2019-05-13 07:35:11 | Catalyst Pharmaceutical CPRX Reports Q1 Loss, Tops Revenue Estimates
2019-05-13 06:27:28 | Catalyst: 1Q Earnings Snapshot
2019-05-11 08:40:14 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs